Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

February 07, 2016 10:24 PM ET


Company Overview of Proteostasis Therapeutics, Inc.

Company Overview

Proteostasis Therapeutics, Inc., a biopharmaceutical company, develops therapeutics to treat protein conformational diseases. The company offers disease-modifying therapeutics for cystic fibrosis; and also develops treatments for diseases caused by an imbalance in the proteostasis network and characterized by defects in protein folding, trafficking, and clearance, including genetic, neurodegenerative, and retinal degenerative diseases. Its lead product candidate is PTI-428, an orally bioavailable cystic fibrosis transmembrane conductance regulator modulator belonging to the amplifier class. The company was formerly known as Proteoguard, Inc. and changed its name to Proteostasis Therapeutics,...

200 Technology Square

4th Floor

Cambridge, MA 02139

United States

Founded in 2006

42 Employees



Key Executives for Proteostasis Therapeutics, Inc.

Chief Executive Officer, President and Director
Age: 43
Interim Chief Financial Officer
Age: 48
Chief Medical Officer and Executive Vice President
Age: 46
Senior Vice President of Drug Discovery
Age: 53
Principal Accounting Officer
Age: 42
Compensation as of Fiscal Year 2015.

Proteostasis Therapeutics, Inc. Key Developments

Proteostasis Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt

Proteostasis Therapeutics, Inc. filed its Annual on Dec 23, 2015 for the period ending Dec 31, 2014. In this report its auditor, PricewaterhouseCoopers LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.

Proteostasis Therapeutics Incorporated Names Ben Munoz as Senior Vice President, Drug Discovery

Proteostasis Therapeutics Incorporated has named Ben Munoz, PhD, as its senior vice president, Drug Discovery. Dr. Munoz will be responsible for all of the company's drug discovery research activities and operations. He will also be responsible for expanding the pipeline with new drug candidates by managing activities related to hit identification, lead optimisation, drug candidate selection and all related aspects of chemistry, manufacturing and controls. Dr. Munoz joined Proteostasis in 2013.

Proteostasis Therapeutics, Inc. Presents at Leerink Partners 4th Annual Rare Disease Roundtable, Sep-30-2015 11:55 AM

Proteostasis Therapeutics, Inc. Presents at Leerink Partners 4th Annual Rare Disease Roundtable, Sep-30-2015 11:55 AM. Venue: Le Parker Meridian, New York, New York, United States. Speakers: Markus Haeberlein, Chief Scientific Officer and Senior Vice President.

Similar Private Companies By Industry

Company Name Region
GreenLight Biosciences, Inc. United States
Tonbo Biotechnologies Corporation United States
Symic Holdings, LLC United States
RGene Therapeutics, Inc. United States
VisiGen Biotechnologies, Inc. United States

Recent Private Companies Transactions

Private Placement
September 1, 2015

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Proteostasis Therapeutics, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at